4.7 Article

Discovery of Dioxino[2,3-f]quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice

Journal

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 175, Issue -, Pages 349-356

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2019.04.015

Keywords

VEGFR-2 inhibition; Dioxinoquinazoline derivatives; Anti-Tumor; Toxicity assay

Funding

  1. Beijing Scitech-MQ Pharmaceuticals Limited [SITG002]
  2. Beijing Key Laboratory for Green Catalysis and Separation
  3. Beijing Key Laboratory of Environmental Viral Oncology

Ask authors/readers for more resources

Twelve 2,3-dihydro-[1,4]-dioxino(2,3-flguinazoline derivatives were designed and evaluated as vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitors. The most half-maximal inhibitory concentration (IC50) values of them were less than 10 nM. Among these compounds, 13d displayed highly effective inhibitory activity against VEGFR-2 (IC50 = 2.4 nM) and excellent antiproliferative activities against human umbilical vein endothelial cells (HUVECs) (IC50 =1.2 nM). When anti-tumor animal experiments were carried out in mice, the tumor almost disappeared (TGI = 133.0%) after six days of administration of 13d. Therefore, 13d was a potential and effective anticancer agent. The binding conformations were respectively compared between VEGFR-2 with 13d and leading compound lenvatinib, and shows that they have similar binding modes. (C) 2019 Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available